Open Targets Platform: new developments and updates two years on

Denise Carvalho‐Silva(European Bioinformatics Institute), Andrea Pierleoni(European Bioinformatics Institute), Miguel Pignatelli(European Bioinformatics Institute), Chuang Kee Ong(European Bioinformatics Institute), Luca Fumis(European Bioinformatics Institute), Nikiforos Karamanis(European Bioinformatics Institute), Miguel Carmona(European Bioinformatics Institute), Adam Faulconbridge(European Bioinformatics Institute), Andrew Hercules(European Bioinformatics Institute), Elaine McAuley(European Bioinformatics Institute), Alfredo Miranda(European Bioinformatics Institute), Gareth Peat(European Bioinformatics Institute), Michaela Spitzer(European Bioinformatics Institute), Jeffrey C. Barrett(Wellcome Sanger Institute), David G. Hulcoop(Age UK), Eliseo Papa(Biogen (United States)), Gautier Koscielny(Age UK), Ian Dunham(European Bioinformatics Institute)
Nucleic Acids Research
October 26, 2018
Cited by 525Open Access
Full Text

Abstract

The Open Targets Platform integrates evidence from genetics, genomics, transcriptomics, drugs, animal models and scientific literature to score and rank target-disease associations for drug target identification. The associations are displayed in an intuitive user interface (https://www.targetvalidation.org), and are available through a REST-API (https://api.opentargets.io/v3/platform/docs/swagger-ui) and a bulk download (https://www.targetvalidation.org/downloads/data). In addition to target-disease associations, we also aggregate and display data at the target and disease levels to aid target prioritisation. Since our first publication two years ago, we have made eight releases, added new data sources for target-disease associations, started including causal genetic variants from non genome-wide targeted arrays, added new target and disease annotations, launched new visualisations and improved existing ones and released a new web tool for batch search of up to 200 targets. We have a new URL for the Open Targets Platform REST-API, new REST endpoints and also removed the need for authorisation for API fair use. Here, we present the latest developments of the Open Targets Platform, expanding the evidence and target-disease associations with new and improved data sources, refining data quality, enhancing website usability, and increasing our user base with our training workshops, user support, social media and bioinformatics forum engagement.


Related Papers

No related papers found

Powered by citation graph analysis